EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›MODD

MODD

Modular Medical, Inc.

Next earnings Aug 12, 2026 · consensus $-0.10 EPS, $204K rev

Hold
$4.94
▲ +19.90%
$4.94▼ -78.94%
over 1Y
L $3.30EODHDH $24.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+19.9%
1W+13.8%
1M+1.2%
3M+5.0%
YTD-57.2%
1Y-78.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
D
Valuation
Fair value
Filings
Watch
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy

Conservative balance sheet (liabilities/equity 0.10x).

Revenue (FY2018) $0.00 · FY2018

Modular Medical, Inc. shows $0.00 in FY2018 revenue, and -110.2% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue—————
Gross profit—————
Operating income-$7.34M-$14.9M-$13.9M-$17.5M-$19.0M
Net income-$7.38M-$18.6M-$13.9M-$17.5M-$18.8M
Diluted EPS—-$2.74-$1.15-$0.78-$0.51
Net margin—————

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$255M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.0%
FCF yield-6.8%

Quality & risk

ROIC (est.)-88.1%
Free cash flow-$18.2M
Total debt—
Net cash$13.1M
Altman Z-Score88.07 safe
Piotroski F-Score3/7

Capital returns

Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+66.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Officer / director change2026-05-20
  2. S-3 Shelf registration (potential raise)2026-04-23
  3. 8-K Material agreement2026-04-21
  4. 8-K Other event2026-04-16
  5. 8-K Material event2026-03-31
  6. 8-K Other event2026-03-13
  7. 8-K Material agreement2026-03-06
  8. S-1 Securities registration2026-02-27
  9. 10-Q Quarterly report2026-02-17

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-05-142026-05-20open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-13open ↗EFFECTFiling2026-05-05open ↗SCHEDULE 13GFiling2026-05-04open ↗CORRESPFiling2026-05-01open ↗UPLOADFiling2026-05-01open ↗S-3Filing2026-04-23open ↗8-KPeriod ending 2026-04-192026-04-21open ↗

Quality score

D
ValueGrowthProfitHealthMom.
Value—
GrowthF
ProfitabilityF
Financial healthB-
Momentum—
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$0.00
Net margin
—
ROE
-110.2%
P/E
—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Revenue$0.00
Net income-$18.8M-7.8%
Gross profit$0.00
Operating income-$19.0M-8.7%
Diluted EPS-$0.51+34.6%
Cash & equivalents$13.1M+41.8%
Total assets$18.7M+35.7%
Total liabilities$1.66M-27.0%
Stockholders' equity$17.1M+48.0%
L/E: 0.10x

Frequently asked

Is Modular Medical, Inc. (MODD) a buy?
MODD currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.10x).
What is Modular Medical, Inc.'s quality score?
MODD scores 41.4102564102564/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001074871, latest 10-Q filed 2026-02-17) · EODHD · as of 6/26/2026, 1:09:55 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-03-31
FELSHER STEVEN G
Director
Award25.00
2026-03-31
DeSisto Duane M
Director
Award83.00

Recent news

market news →
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTXBullish
nasdaq.com· 2026-05-21
Modular Medical prices $3.4M offering at $4.50 per share
seekingalpha.com· 2026-04-20
Modular Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementBullish
finance.yahoo.com· 2026-04-16
Most and least shorted healthcare stocks with up to $2B market capBullish
seekingalpha.com· 2026-02-16
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also AdvanceBullish
nasdaq.com· 2026-01-15
After-Hours Gainers: A Quiet Session With A Standout Biotech SurgeBullish
nasdaq.com· 2025-12-17

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score41 vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity-110.2% vs 12.3%
P/E— vs 25.5